New trials are currently evaluating the role of perioperative androgen receptor–targeted therapy or Lu-labeled PSMA radioligands in locally advanced/cN1 prostate cancer, which might also lead to a change in treatment algorithms [22,23]. This evidence concerns the gene AR and prostate carcinoma.